NCT01531361View on ClinicalTrials.gov

Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

February 6, 2012

Primary Completion Date

January 13, 2021

Study Completion Date

January 13, 2021

Conditions
Advanced Malignant NeoplasmBRAF Gene MutationMetastatic Malignant NeoplasmRecurrent Malignant NeoplasmRefractory Malignant Neoplasm
Interventions
DRUG

Crizotinib

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Pharmacological Study

Correlative studies

DRUG

Sorafenib Tosylate

Given PO

DRUG

Vemurafenib

Given PO

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT01531361 - Vemurafenib With Sorafenib Tosylate or Crizotinib in Treating Patients With Advanced Malignancies With BRAF Mutations | Biotech Hunter | Biotech Hunter